IMMUNOENZYMATIC AND ELECTROCARDIOGRAPHIC FINDINGS IN PATIENTS WITH DECOMPENSATED HEART FAILURE SECONDARY TO PRIOR ACUTE MYOCARDIAL INFARCTION BEFORE AND AFTER TREATMENT

Authors

  • Kh. V. Levandovska Ivano-Frankivsk National Medical University
  • Kh. V. Levandovska Ivano-Frankivsk National Medical University

DOI:

https://doi.org/10.21802/2304-7437-2019-6(58)-38-48

Abstract

Chronic heart failure (HF) remains a potentially dangerous fatal stage of any cardiovascular disease demonstrating a steady increase in the prevalence among the general population that is accompanied by a progressive increase in the health care costs for improving the patients’ health or clinical status, increasing their quality of life, reducing the risk of death. There is wide interest in studying biomarkers in HF as they can improve the diagnosis, predict the occurrence of its decompensation, as well as help in assessing treatment effects.

The objective of the study was to assess the value of determining the plasma concentration of NT-proBNP and ST2 in the patients with decompensated HF and prior acute myocardial infarction (MI) after treatment with succinic acid and arginine preparations under electrocardiographic control.

Materials and methods. There were examined 120 patients with Q-QS wave and non-Q wave MI, stage II A-B decompensated chronic HF according to the classification proposed by Vasylenko V.Kh. and Strazhesko M.D., the NYHA functional class (FC) III-IV. The patients with Q-QS wave MI (60 individuals) were divided into 4 groups depending on the treatment method. The patients with non-Q wave MI (60 individuals) were divided into 4 analogous groups.

Study groups were homogenous by age, gender, disease severity, duration of the post-infarction period, clinical signs of decompensation, that served as a basis for inclusion of patients in the study.

Results. There was analyzed the  dynamics of changes in ECG indicators in the patients with decompensated HF and prior MI under the influence of therapy. At the beginning of controlled treatment, most patients developed signs of left ventricular hypertrophy (LVH) and reduced bioelectrical activity. Therapy applied helped reduce the incidence of sinus tachycardia cases.

The studied preparations were shown to have the positive effect on the dynamics of heart rhythm disorders in the patients with decompensated HF and prior Q wave MI.  During treatment of the patients with prior non-Q wave MI, the positive dynamics in ECG findings, namely reduction in cardiac bioelectrical activity and LHV, was observed. Myocardial bioelectrical activity had a clear tendency to reduce 1 month, and especially 2 months, after treatment. When analyzing the dynamics of changes in blood levels of NT-proBNP, there was observed its significant reduction in all the groups of the patients after the end of treatment. According to the data presented in Table 1, all the treatment schemes proposed led to a significant reduction in serum levels of this peptide after treatment ended.

Conclusions. Thus, we can conclude that the treatment of patients with decompensated HF secondary to prior Q-QS wave or non-Q wave MI with succinic acid and arginine preparations possessing anti-ischemic, antianginal, anti-hypoxic, angioprotective effects, allows providing adequate treatment of decompensated HF, as evidenced by the positive dynamics of changes in immunoenzymatic and electrocardiographic findings. Therefore, we plan to develop an algorithm for assessing the quality of therapy, as well as to determine the frequency and time periods of using these peptides for making therapeutic decisions.

 

References

Біловол А.Н, Бобронникова Л.П. та ін. (2014) Патогенетичні аспекти розвитку хронічної серцевої недостатності в залежності від статі та віку. Український терапевтичний журнал 3–4:9–13.

Воронков Л.Г, Філатова О.Л. та ін. (2017) Виживаність упродовж 24 місяців та її предиктори в пацієнтів з хронічною серцевою недостатністю і зниженою фракцією викиду лівого шлуночка залежно від статі Український кардіологічний журнал 6: 50–54.

Целуйко В.Й, Міщук Н.Є. (2017) Дослідження показників, що впливають на клінічний прогноз та ремоделювання серця у віддаленому періоді у хворих на інфаркт міокарду з елевацією сегменту ST Scientific Journal «ScienceRise: Medical Science» 11(19): 36–43.

Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357-2368. DOI:10.1016/j.jacc.2007.09.021 PMID:18154959.

Dieplinger B, Januzzi Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T. Analytical and clinical evaluation of a novel high-sensitivity as-say for measurement of soluble ST2 in human plasma—the Presage ST2 as-say, Clin. Chim. Acta. 2009;409:33–40. DOI: 10.1016/j.cca.2009.08.010. PMID:19699192.

Echouffo-Tcheugui JB, Greene SJ, Papadimitriou L, Zannad F, Yancy CW, Gheorghiade M, Butler J. Population risk prediction models for incident heart failure: a systematic review. Circ Heart Fail. 2015 May; 8(3):438-47. DOI: 10.1161/CIRCHEARTFAILURE.114.001896. PMID: 25737496.

Maisel AS, Duran JM, Wettersten N. Natriuretic peptides in heart failure. Heart Failure Clinics. 2019 Feb;5(1):44–49. DOI: 10.15420/cfr.2018.26.1.

Reichlina T, Abächerlib R, Twerenbolda R, Kühnea M, Schaera B, Muel-lera C et all. Advanced ECG in 2016: is there more than just a tracing? Swiss medical weekly. 2016;146;w14303. doi:10.4414/smw.2016.14303.

Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic heart diseases. Am J Cardiol. 2010 May;159(5):788-94. DOI: 10.1016/j.ahj.2010.02.022. PMID:2043518.

Stienen S, Salah K, Dickhoff C, et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements until a 30% reduction is attained during acute decompensated heart failure admissions and comparison with dis-charge NT-proBNP levels: implications for in-hospital guidance of treatment. J Card Fail. 2015 Nov;21(11):930-4. DOI: 10.1016/j.cardfail. 2015.07.011. PMID:26216495.

van Deursen CJ, Vernooy K, Dudink E, Bergfeldt L, Crijns HJ, Prinzen FW. Vectorcardiographic QRS area as a novel predictor of response to cardiac resynchronization therapy. J Electrocardiol. 2015;48:45–52. DOI: 10.1016/j.jelectrocard.2014.10.003. PMID: 25453196.

Yucel O, Gul I, Zararsits A, Demirpence O, Yucel H, Cinar Z et al. Association of soluble ST2 with functional capacity in outpatients with heart failure. Herz. 2018 Aug;43(5):455-460. DOI: 10.1007/s00059-017-4590-1. PMID:28653113.

Wang H, Liang X, Luo G, Ding M, Liang Q. Protection effect of nicotinamide on cardiomyoblast hypoxia/re-oxygenation injury: study of cellular mitochondrial metabolism. Molecular BioSystems. 2016;12(7):2257–2264. DOI:10.1039/c6mb00108d.

Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. (2016);13:368–78. DOI:10.1038/nrcardio.2016.25. PMID:26935038.

Zile MR, Claggett BL, Prescott MF, McMurray JJV, Packer M, Rouleau JL, Solomon SD. Prognostic implications of changes in N-Terminal pro-B-type natriuretic peptide in patients with heart failure. Journal of the American College of Cardiology. 2017 Oct;10(10). pii: e004409. DOI: 10.1161/CIRCHEARTFAILURE.117.004409. PMID:29018174.

Published

2019-12-26

How to Cite

Levandovska, K. V. ., & Levandovska, K. V. . (2019). IMMUNOENZYMATIC AND ELECTROCARDIOGRAPHIC FINDINGS IN PATIENTS WITH DECOMPENSATED HEART FAILURE SECONDARY TO PRIOR ACUTE MYOCARDIAL INFARCTION BEFORE AND AFTER TREATMENT. PRECARPATHIAN BULLETIN OF THE SHEVCHENKO SCIENTIFIC SOCIETY Pulse, (6(58), 38-48. https://doi.org/10.21802/2304-7437-2019-6(58)-38-48